본문 바로가기
KERD
논문KCI 등재

성인 여성에서 혈청 Osteoprotegerin 농도와 골대사의 관련성

Relationship between serum osteoprotegerin levels and bone mineral metabolism in women

박성우|이은정|이원영|윤은주|최문기|박철영|오은숙|유형준|백기현|강무일|오기원|박경창
대한내과학회 (The Korean Association Of Internal Medicine)|2004.01|대한내과학회지 (The Korean Journal of Medicine)|제66권 제1호|pp. 11-18

2

조회

0

다운로드

2

인용

0

참고문헌

주제분류내과학

초록

Abstract

Background:Osteoprotegerin (OPG) is a recently identified cytokine that acts as a decoy receptor for the RANK ligand. OPG has been shown to be an important inhibitor of osteoclastogenesis in animal models. The relationship between circulating OPG levels and female bone status in human populations is unclear. Thus, the aim of this study was to investigate the relationship between circulating OPG levels and bone mineral metabolism in Korean women. Methods:Subjects were 287 women aged 37～73 (mean age, 51.5 yr). Serum concentrations of OPG were determined by ELISA. Biochemical markers of bone turnover and follicle stimulating hormone (FSH) were measured by standard methods. Bone mineral density at lumbar spine and femur neck were measured by dual energy X-ray absorptiometry. Results:We observed a significant positive association between circulating OPG levels and urine calcium excretion (r=0.128; p<0.05). Although circulating OPG levels were not significantly correlated to urine deoxypyridinoline levels (r=0.105; p=0.076), but there was a weak trend in it. We found that mean OPG levels were about 11% greater in postmenopausal women (mean±SD, 1358.5±380.0 pg/mL) than in premenopausal women (1228.8±407.7 pg/mL; p<0.001). There was a significant positive relationship between circulating OPG levels and serum FSH levels (r=0.172; p<0.01). There was a non-significant relationship between circulating OPG levels and bone mineral density at lumbar spine and femur neck. Conclusion:In conclusion, our data shows that the circulating OPG levels are associated with urine calciumexcretion and serum FSH levels in Korean women. These data suggest that OPG may be an important paracrine mediator of female bone metabolism in human populations.

참고문헌 (33)

  1. "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density", 89, pp.309~319 (1997)
  2. "Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis", 234, pp.137~142 (1997)
  3. "TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption", 12, pp.845~854 (1998)
  4. "Osteoclast differentiation factor is a ligand for osteoprotegerin", osteoclastogenesis-inhibitory factor and is identical to TRANCE, pp.1998, 95[DOI]
  5. "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", 93, pp.165~176 (1998)
  6. "TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells", 272, pp.25190~25194 (1997)
  7. "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function", 390, pp.175~179 (1997)
  8. "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis", 397, pp.315~323
  9. "Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor", osteoprotegerin, 1998, pp.247, 610~615
  10. "Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification", 12, pp.1260~1268 (1998)
  11. "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL", 273, pp.14363~14367 (1998)
  12. "Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis", 215, pp.339~343 (1998)
  13. "Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts", 242, pp.703~709 (1998)
  14. "Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast", 250, pp.229~234 (1998)
  15. "Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts", 251, pp.796~801 (1998)
  16. "The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts", 145, pp.527~538 (1999)
  17. "Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function", 163, pp.434~442 (1999)
  18. "Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis", 140, pp.4382~4389 (1999)
  19. "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG) a mechanism by which OPG", OCIF inhibits osteoclastogenesis in vitro, 1998, pp.139, 1329~1337
  20. "Immunological characterization of circulating osteoprotegerin", osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis, 1999, pp.14, 518~527
  21. "Correlates of osteoprotegerin levels in women and men", 13, pp.394~399 (2002)
  22. "Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status", 86, pp.3162~3165 (2001)
  23. "Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study", 88, pp.1014~1018 (2003)
  24. "Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women", 87, pp.4470~4475 (2002)
  25. "Skeletal effects of estrogen", 15, pp.275~300 (1994)
  26. "Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis", 11, pp.1043~1051 (1996)
  27. "Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis", 332, pp.305~311 (1995)
  28. "Cytokines, bone remodeling, and estrogen deficiency: a 1998 update", 23, pp.75~81 (1998)
  29. "Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells", 140, pp.4367~4370 (1999)
  30. "Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells", 25, pp.785~790 (2002)
  31. "The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts", 32, pp.136~141 (2003)
  32. "17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha", 142, pp.2205~2212 (2001)
  33. "Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG", RANKL (osteoprotegerin, pp.2001, 171[DOI]

이 간행물의 다른 논문 (4건)

순환기 내과 환자를 대상으로 한 심부전의 정도와 NT-pro BNP의 혈중 농도와의 관계 분석 : 순환기 내과 외래 환자와 입원 환자를 중심으로권현철, 이수연, 김준수, 송봉근, 김덕경, 강민경, 전은석, 김용훈, 김필호, 이종구, 홍경표, 도준형, 안석진, 이상훈, 오혜림, 박정의, 김현중, 성지동, 이상철pp. 33-40심방세동의 유발과 유지에 관여하는 인자에 관한 연구임지현, 안영근, 정명호, 조정관, 윤남식, 박형욱, 김한균, 홍영준, 김원, 김주한, 고점석, 박종춘, 강정채, 배열, 양보라pp. 41-47돼지 관상동맥 스텐트 재협착 모델에서 Carvedilol 부착BiodivYsioTM 스텐트의 신생내막 증식 억제 효과홍영준, 강정채, 박종춘, 이승현, 차광수, 조정관, 김주한, 안영근, 김무현, 김원, 정명호, 박옥영pp. 48-57H. pylori 제균으로 완해된 위의 고도 MALT 림프종 1예장흥문, 허주령, 엄대운, 김태원, 강윤구, 류민희, 황창연pp. 95-99
원문 보기